407 related articles for article (PubMed ID: 15616603)
1. RNAi-mediated gene-targeting through systemic application of polyethylenimine (PEI)-complexed siRNA in vivo.
Urban-Klein B; Werth S; Abuharbeid S; Czubayko F; Aigner A
Gene Ther; 2005 Mar; 12(5):461-6. PubMed ID: 15616603
[TBL] [Abstract][Full Text] [Related]
2. A low molecular weight fraction of polyethylenimine (PEI) displays increased transfection efficiency of DNA and siRNA in fresh or lyophilized complexes.
Werth S; Urban-Klein B; Dai L; Höbel S; Grzelinski M; Bakowsky U; Czubayko F; Aigner A
J Control Release; 2006 May; 112(2):257-70. PubMed ID: 16574264
[TBL] [Abstract][Full Text] [Related]
3. Polyethylenimines for RNAi-mediated gene targeting in vivo and siRNA delivery to the lung.
Günther M; Lipka J; Malek A; Gutsch D; Kreyling W; Aigner A
Eur J Pharm Biopharm; 2011 Apr; 77(3):438-49. PubMed ID: 21093588
[TBL] [Abstract][Full Text] [Related]
4. Gene silencing through RNA interference (RNAi) in vivo: strategies based on the direct application of siRNAs.
Aigner A
J Biotechnol; 2006 Jun; 124(1):12-25. PubMed ID: 16413079
[TBL] [Abstract][Full Text] [Related]
5. RNA interference-mediated gene silencing of pleiotrophin through polyethylenimine-complexed small interfering RNAs in vivo exerts antitumoral effects in glioblastoma xenografts.
Grzelinski M; Urban-Klein B; Martens T; Lamszus K; Bakowsky U; Höbel S; Czubayko F; Aigner A
Hum Gene Ther; 2006 Jul; 17(7):751-66. PubMed ID: 16839274
[TBL] [Abstract][Full Text] [Related]
6. Delivery of unmodified bioactive ribozymes by an RNA-stabilizing polyethylenimine (LMW-PEI) efficiently down-regulates gene expression.
Aigner A; Fischer D; Merdan T; Brus C; Kissel T; Czubayko F
Gene Ther; 2002 Dec; 9(24):1700-7. PubMed ID: 12457284
[TBL] [Abstract][Full Text] [Related]
7. Nonviral in vivo delivery of therapeutic small interfering RNAs.
Aigner A
Curr Opin Mol Ther; 2007 Aug; 9(4):345-52. PubMed ID: 17694447
[TBL] [Abstract][Full Text] [Related]
8. Polyethylenimine PEI F25-LMW allows the long-term storage of frozen complexes as fully active reagents in siRNA-mediated gene targeting and DNA delivery.
Höbel S; Prinz R; Malek A; Urban-Klein B; Sitterberg J; Bakowsky U; Czubayko F; Aigner A
Eur J Pharm Biopharm; 2008 Sep; 70(1):29-41. PubMed ID: 18499413
[TBL] [Abstract][Full Text] [Related]
9. In vivo pharmacokinetics, tissue distribution and underlying mechanisms of various PEI(-PEG)/siRNA complexes.
Malek A; Merkel O; Fink L; Czubayko F; Kissel T; Aigner A
Toxicol Appl Pharmacol; 2009 Apr; 236(1):97-108. PubMed ID: 19371615
[TBL] [Abstract][Full Text] [Related]
10. A novel siRNA-lipoplex technology for RNA interference in the mouse vascular endothelium.
Santel A; Aleku M; Keil O; Endruschat J; Esche V; Fisch G; Dames S; Löffler K; Fechtner M; Arnold W; Giese K; Klippel A; Kaufmann J
Gene Ther; 2006 Aug; 13(16):1222-34. PubMed ID: 16625243
[TBL] [Abstract][Full Text] [Related]
11. Polyethylenimine (PEI)/siRNA-mediated gene knockdown in vitro and in vivo.
Höbel S; Aigner A
Methods Mol Biol; 2010; 623():283-97. PubMed ID: 20217558
[TBL] [Abstract][Full Text] [Related]
12. Polyethylenimine/small interfering RNA-mediated knockdown of vascular endothelial growth factor in vivo exerts anti-tumor effects synergistically with Bevacizumab.
Höbel S; Koburger I; John M; Czubayko F; Hadwiger P; Vornlocher HP; Aigner A
J Gene Med; 2010 Mar; 12(3):287-300. PubMed ID: 20052738
[TBL] [Abstract][Full Text] [Related]
13. Cholesteryl oligoarginine delivering vascular endothelial growth factor siRNA effectively inhibits tumor growth in colon adenocarcinoma.
Kim WJ; Christensen LV; Jo S; Yockman JW; Jeong JH; Kim YH; Kim SW
Mol Ther; 2006 Sep; 14(3):343-50. PubMed ID: 16765648
[TBL] [Abstract][Full Text] [Related]
14. RNA interference in the mouse vascular endothelium by systemic administration of siRNA-lipoplexes for cancer therapy.
Santel A; Aleku M; Keil O; Endruschat J; Esche V; Durieux B; Löffler K; Fechtner M; Röhl T; Fisch G; Dames S; Arnold W; Giese K; Klippel A; Kaufmann J
Gene Ther; 2006 Sep; 13(18):1360-70. PubMed ID: 16625242
[TBL] [Abstract][Full Text] [Related]
15. Atelocollagen-mediated local and systemic applications of myostatin-targeting siRNA increase skeletal muscle mass.
Kinouchi N; Ohsawa Y; Ishimaru N; Ohuchi H; Sunada Y; Hayashi Y; Tanimoto Y; Moriyama K; Noji S
Gene Ther; 2008 Aug; 15(15):1126-30. PubMed ID: 18323791
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery.
Landen CN; Chavez-Reyes A; Bucana C; Schmandt R; Deavers MT; Lopez-Berestein G; Sood AK
Cancer Res; 2005 Aug; 65(15):6910-8. PubMed ID: 16061675
[TBL] [Abstract][Full Text] [Related]
17. Folate-linked lipid-based nanoparticles for synthetic siRNA delivery in KB tumor xenografts.
Yoshizawa T; Hattori Y; Hakoshima M; Koga K; Maitani Y
Eur J Pharm Biopharm; 2008 Nov; 70(3):718-25. PubMed ID: 18647651
[TBL] [Abstract][Full Text] [Related]
18. Materializing the potential of small interfering RNA via a tumor-targeting nanodelivery system.
Pirollo KF; Rait A; Zhou Q; Hwang SH; Dagata JA; Zon G; Hogrefe RI; Palchik G; Chang EH
Cancer Res; 2007 Apr; 67(7):2938-43. PubMed ID: 17409398
[TBL] [Abstract][Full Text] [Related]
19. In vivo gene silencing in solid tumors by targeted electrically mediated siRNA delivery.
Golzio M; Mazzolini L; Ledoux A; Paganin A; Izard M; Hellaudais L; Bieth A; Pillaire MJ; Cazaux C; Hoffmann JS; Couderc B; Teissié J
Gene Ther; 2007 May; 14(9):752-9. PubMed ID: 17344906
[TBL] [Abstract][Full Text] [Related]
20. Atelocollagen-mediated synthetic small interfering RNA delivery for effective gene silencing in vitro and in vivo.
Minakuchi Y; Takeshita F; Kosaka N; Sasaki H; Yamamoto Y; Kouno M; Honma K; Nagahara S; Hanai K; Sano A; Kato T; Terada M; Ochiya T
Nucleic Acids Res; 2004 Jul; 32(13):e109. PubMed ID: 15272050
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
